Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 6 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 5 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Integrating genetic testing into routine oncology care in the UK

Dr Joslyn Ngu
04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Despite the many advantages of genetic testing, patients with ovarian cancer are historically under-referred, said Dr Angela George, consultant oncogenetics and clinical lead of the Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, UK. The reasons for this include the failures to take family history; to recognize family history; and to refer.

The integration of genetic testing into routine oncology care requires the education of clinicians, oncologists and specialized nurses so they are well-equipped to take consent from patients for genetic testing, said George. Once patients who fit the pre-agreed criteria for testing gives their consent, healthcare professionals in the clinic can obtain the necessary blood samples and send them together with the forms to a genetics centre. This will reduce the need for patients to make additional appointments with the genetics department, which means no extra appointments and no waiting for referral, she said.

In the UK, a training programme for healthcare professionals to perform BRCA gene testing for breast and ovarian cancer is available on Youtube and a certificate of completion is provided, said George.

Ovarian cancer is a good example to showcase the benefits of mainstreaming genetic testing. An estimated 15 percent of ovarian cancer have a BRCA 1 or BRCA 2 mutation. [Sci Rep 2016;6:29506. Doi: 10.1038/srep29506]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 6 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 5 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).